Predicting T790M mutation status in non-small cell lung cancer based on radiomics: A systematic review and meta-analysis

08 Jul 20264 min read0 viewsJournal Feed

GIST (Key Takeaways)

by Hongyang Chen, Bingjie Fan, Mengqi Yuan, Dandan Wang, Chenxi Qiao, Na Qiu, Xiaomin Quan, Wei Hou Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have revolutionized the prognosis for patients with EGFR-mutant lung cancer. The emergence of the T790M resistance mutation compromises the efficacy of EGFR-TKI therapy.
Therefore, assessing EGFR T790M mutation status during non-small cell lung cancer (NSCLC) treatment is crucial for improving NSCLC prognosis. Method PubMed, Embase, Web of Science databases, China National Knowledge Infrastructure, and Wanfang as primary sources were systematically searched up to January 1, 2026.
To assess the risk of bias and study quality, we employed the Quality Assessment of Diagnostic Accuracy Studies (QUADAS) tool and the Radiomics Quality Score version 2.0 (RQS). The diagnostic accuracy of radiomics for detecting T790M in NSCLC patients was evaluated by calculating the area under the curve (AUC), sensitivity, specificity, and accuracy for each study.
Results This meta-analysis analyzed 13 studies with 2,654 patients. The pooled AUC, sensitivity, and specificity of internal validation models were 0.91, 0.73, and 0.95, respectively.